 |
Neutrophil-endothelial interaction inhibitor |
|---|---|
| Trade Name | Cylexin |
| Orphan Indication | Post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension |
| USA Market Approval | USA |
| USA Designation Date | 1993-12-22 00:00:00 |
| Sponsor | Cytel Corporation;3525 John Hopkins Court;San Diego, California, 92121 |
